Back to Search Start Over

Differences in the Evolution of Clinical, Biochemical, and Hematological Indicators in Hospitalized Patients with COVID-19 According to Their Vaccination Scheme: A Cohort Study in One of the World’s Highest Hospital Mortality Populations

Authors :
Martha A. Mendoza-Hernandez
Jose Guzman-Esquivel
Marco A. Ramos-Rojas
Vanessa V. Santillan-Luna
Carmen A. Sanchez-Ramirez
Gustavo A. Hernandez-Fuentes
Janet Diaz-Martinez
Valery Melnikov
Fabian Rojas-Larios
Margarita L. Martinez-Fierro
Daniel Tiburcio-Jimenez
Iram P. Rodriguez-Sanchez
Osiris G. Delgado-Enciso
Ariana Cabrera-Licona
Ivan Delgado-Enciso
Source :
Vaccines, Vol 12, Iss 1, p 72 (2024)
Publication Year :
2024
Publisher :
MDPI AG, 2024.

Abstract

COVID-19 vaccines primarily prevent severe illnesses or hospitalization, but there is limited data on their impact during hospitalization for seriously ill patients. In a Mexican cohort with high COVID-19 mortality, a study assessed vaccination’s effects. From 2021 to 2022, 462 patients with 4455 hospital days were analyzed. The generalized multivariate linear mixed model (GENLINMIXED) with binary logistic regression link, survival analysis and ROC curves were used to identify risk factors for death. The results showed that the vaccinated individuals were almost half as likely to die (adRR = 0.54, 95% CI = 0.30–0.97, p = 0.041). When stratifying by vaccine, the Pfizer group (BNT162b2) had a 2.4-times lower risk of death (adRR = 0.41, 95% CI = 0.2–0.8, p = 0.008), while the AstraZeneca group (ChAdOx1-S) group did not significantly differ from the non-vaccinated (adRR = 1.04, 95% CI = 0.5–2.3, p = 0.915). The Pfizer group exhibited a higher survival, the unvaccinated showed increasing mortality, and the AstraZeneca group remained intermediate (p = 0.003, multigroup log-rank test). Additionally, BNT162b2-vaccinated individuals had lower values for markers, such as ferritin and D-dimer. Biochemical and hematological indicators suggested a protective effect of both types of vaccines, possibly linked to higher lymphocyte counts and lower platelet-to-lymphocyte ratio (PLR). It is imperative to highlight that these results reinforce the efficacy of COVID-19 vaccines. However, further studies are warranted for a comprehensive understanding of these findings.

Details

Language :
English
ISSN :
2076393X
Volume :
12
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
edsdoj.089314676c274acab6932f74c1377c9f
Document Type :
article
Full Text :
https://doi.org/10.3390/vaccines12010072